Camrelizumab
- Generic Name
- Camrelizumab
- Drug Type
- Biotech
- CAS Number
- 1798286-48-2
- Unique Ingredient Identifier
- 73096E137E
- Background
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
- Indication
⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。
⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。
⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。
⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。
Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC
- Conditions
- Lung DiseasesNeoplasmsRespiratory Tract DiseasesNon-small-cell Lung CancerThoracic Neoplasms
- Interventions
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2019-10-21
- Lead Sponsor
- Sichuan Cancer Hospital and Research Institute
- Target Recruit Count
- 20
- Registration Number
- NCT04133337
- Locations
- 🇨🇳
Sichuan Cancer Hospital, Chengdu, Sichuan, China
A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- First Posted Date
- 2019-10-17
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 46
- Registration Number
- NCT04129996
- Locations
- 🇨🇳
Zhi-Ming Shao, Shanghai, China
A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC
- Conditions
- PD-1 AntibodyLung Cancer Stage IINon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2019-09-27
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Target Recruit Count
- 38
- Registration Number
- NCT04108013
Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer
- Conditions
- NSCLC Stage IV
- Interventions
- Other: Camrelizumab plus microwave ablation
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- Shandong Provincial Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT04102982
- Locations
- 🇨🇳
Binzhou Medical University Hospital, Binzhou, Shandong, China
🇨🇳Liaocheng Cancer Hospital, Liaocheng, Shandong, China
🇨🇳Jinan Military General Hospital, Jinan, Shandong, China
Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- Zhongshan Hospital Xiamen University
- Target Recruit Count
- 62
- Registration Number
- NCT04067986
- Locations
- 🇨🇳
Zhongshan Hospital Affiliated to Xiamen University, Xiamen, Fujian, China
Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer
- Conditions
- Recurrent Platinum-resistant Ovarian Cancer
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT04068974
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Beijing Sanbo Brain Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT04070040
- Locations
- 🇨🇳
Sanbo Brain Hospital Capital Medical University, Beijing, China
Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma
- Conditions
- Classical Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04067037
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
Camrelizumab Combined With Apatinib for Recurrent Resistant GTN
- Conditions
- Gestational Trophoblastic Disease
- Interventions
- First Posted Date
- 2019-08-06
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04047017
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma
- Conditions
- Effect of DrugsPediatric CancerProgression
- Interventions
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Peking University People's Hospital
- Registration Number
- NCT04044378
- Locations
- 🇨🇳
Lu Xie, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.